Relmapirazin

Relmapirazin
Clinical data
Trade namesLumitrace
Other namesMB-102
ATC code
Identifiers
  • (2R)-2-[[3,6-Diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC12H16N6O8
Molar mass372.294 g·mol−1
3D model (JSmol)
  • C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O
  • InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1
  • Key:XHNJXRDGTITISI-QWWZWVQMSA-N

Relmapirazin (MB-102) is an investigational fluorescent tracer that is exclusively excreted renally and is used to measure glomerular filtration rate of the kidneys.[1][2][3][4][5][6][7]

Using plasma sampling, relmapirazin has been shown to have the same properties and accuracy as iohexol for determining glomerular filtration rate in human subjects of varying kidney function.[8] Furthermore, transdermal optical detection of the change in concentration of intravenously injected relmapirazin has been used to estimate glomerular filtration rate with excellent accuracy in human subjects of varying kidney function and skin color.[9]

References

  1. ^ Dorshow RB, Shieh JJ, Debreczeny MP (17 March 2023). "Clinical results from a pilot multi-center study using a novel fluorescent tracer agent for renal function measurement". In Raghavachari R, Berezin MY (eds.). Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XIV. p. 19. doi:10.1117/12.2648541. ISBN 978-1-5106-5901-8. S2CID 257614179.
  2. ^ Orieux A, Samson C, Pieroni L, Drouin S, Dang Van S, Migeon T, et al. (5 June 2023). "Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model". Scientific Reports. 13 (1): 9130. Bibcode:2023NatSR..13.9130O. doi:10.1038/s41598-023-36124-1. ISSN 2045-2322. PMC 10241877. PMID 37277538.
  3. ^ Jang SM, Shieh JJ, Riley IR, Dorshow RB, Mueller BA (July 2023). "Adsorption and Clearance of the Novel Fluorescent Tracer Agent MB-102 During Continuous Renal Replacement Therapy: In Vitro Results". ASAIO Journal. 69 (7): 702–707. doi:10.1097/MAT.0000000000001943. ISSN 1058-2916. PMC 10298171. PMID 37071749.
  4. ^ Rosner MH, Sprangers B, Sandhu G, Malyszko J (November 2022). "Glomerular Filtration Rate Measurement and Chemotherapy Dosing". Seminars in Nephrology. 42 (6) 151340. doi:10.1016/j.semnephrol.2023.151340. PMID 37086497. S2CID 258266791.
  5. ^ McMahon BA, Rosner MH (February 2020). "GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer". Kidney360. 1 (2): 141–150. doi:10.34067/KID.0000952019. PMC 8809099. PMID 35372903.
  6. ^ Schneider AG, Molitoris BA (December 2020). "Real-time glomerular filtration rate: improving sensitivity, accuracy and prognostic value in acute kidney injury". Current Opinion in Critical Care. 26 (6): 549–555. doi:10.1097/MCC.0000000000000770. PMID 33002974. S2CID 222173308.
  7. ^ Dorshow RB, Johnson JR, Shieh JJ, Riley IR, Rogers TE, Pino CJ, et al. (July 2023). "Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results". ASAIO Journal. 69 (7): 708–715. doi:10.1097/MAT.0000000000001945. PMC 10298183. PMID 37097973.
  8. ^ Dorshow RB, Debreczeny MP, Goldstein SL, Shieh JJ (October 2024). "Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102)". Kidney International. 106 (4): 679–687. doi:10.1016/j.kint.2024.06.012. PMID 38964736.
  9. ^ Dorshow RB, Debreczeny MP, Goldstein SL (7 February 2025). "GFR Measurement Using Transdermal Detection Methodology". Journal of the American Society of Nephrology. 36 (8): 1592–1602. doi:10.1681/ASN.0000000639. PMC 12342084. PMID 39918882.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.